{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:06:03Z","timestamp":1789664763649,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejphar.2025.177826","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T01:24:12Z","timestamp":1749345852000},"page":"177826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Therapeutic effects of finerenone and exenatide on diabetes-induced heart failure: A combined approach targeting inflammation and oxidative stress"],"prefix":"10.1016","volume":"1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1510-2937","authenticated-orcid":false,"given":"Ay\u015fe","family":"Ko\u00e7ak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emirhan","family":"G\u00fcnek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meliha Koldemir","family":"G\u00fcnd\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6309-0208","authenticated-orcid":false,"given":"G\u00fcll\u00fc","family":"Kaymak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.ejphar.2025.177826_bib1","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1093\/eurheartj\/ehab886","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"issue":"12 Suppl. l","key":"10.1016\/j.ejphar.2025.177826_bib2","doi-asserted-by":"crossref","first-page":"S381","DOI":"10.1177\/09603271211040819","article-title":"Electrocardiographic, hemodynamic, and biochemical evidence on the protective effects of exenatide against phosphine-induced cardiotoxicity in rat model","volume":"40","author":"Bameri","year":"2021","journal-title":"Hum. Exp. Toxicol."},{"issue":"6","key":"10.1016\/j.ejphar.2025.177826_bib3","first-page":"865","article-title":"Diabetic cardiomyopathy revisited","volume":"42","author":"Boudina","year":"2007","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177826_bib4","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","article-title":"Molecular mechanisms of diabetic cardiomyopathy","volume":"57","author":"Bugger","year":"2014","journal-title":"Diabetologia (Berl.)"},{"key":"10.1016\/j.ejphar.2025.177826_bib5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10741-024-10455-1","article-title":"Mineralocorticoid receptor antagonists and heart failure with preserved ejection fraction: current understanding and future prospects","volume":"30","author":"Chen","year":"2025","journal-title":"Heart Fail Rev"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177826_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab."},{"issue":"1210","key":"10.1016\/j.ejphar.2025.177826_bib7","first-page":"45","volume":"47","year":"2005","journal-title":"Med. Lett. Drugs Ther."},{"issue":"11","key":"10.1016\/j.ejphar.2025.177826_bib8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jchf.2022.07.013","article-title":"Finerenone and heart failure outcomes by kidney function\/albuminuria in chronic kidney disease and diabetes","volume":"10","author":"Filippatos","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.ejphar.2025.177826_bib9","first-page":"813","article-title":"Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death","volume":"44","author":"Fiordaliso","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177826_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"Forbes","year":"2013","journal-title":"Physiol. Rev."},{"issue":"9","key":"10.1016\/j.ejphar.2025.177826_bib11","doi-asserted-by":"crossref","first-page":"8640","DOI":"10.18632\/aging.103181","article-title":"Exenatide inhibits NF-\u03baB and attenuates ER stress in diabetic cardiomyocyte models","volume":"12","author":"Fu","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.ejphar.2025.177826_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress","volume":"9","author":"Gonz\u00e1lez-Bl\u00e1zquez","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177826_bib13","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/07853890.2023.2171110","article-title":"Cardiorenal benefits of finerenone: protecting kidney and heart","volume":"55","author":"Gonz\u00e1lez-Juanatey","year":"2023","journal-title":"Ann. Med."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177826_bib14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","article-title":"Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy","volume":"67","author":"Grune","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"21","key":"10.1016\/j.ejphar.2025.177826_bib15","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/ajhp\/zxz179","article-title":"Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus","volume":"76","author":"Guyton","year":"2019","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejphar.2025.177826_bib16","doi-asserted-by":"crossref","first-page":"27770","DOI":"10.3390\/ijms161126059","article-title":"Redox roles of reactive oxygen species in cardiovascular diseases","volume":"16","author":"He","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.177826_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154910","article-title":"Heart failure in diabetes","volume":"125","author":"Jankauskas","year":"2021","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.ejphar.2025.177826_bib18","first-page":"3","article-title":"Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease","volume":"122","author":"Jia","year":"2018","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"11","key":"10.1016\/j.ejphar.2025.177826_bib19","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1172\/JCI106180","article-title":"Diabetogenic action of streptozotocin: relationship of dose to metabolic response","volume":"48","author":"Junod","year":"1969","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177826_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-017-0604-9","article-title":"Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes","volume":"16","author":"Karam","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2025.177826_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/09603271211065975","article-title":"Protective effects of alpha-lipoic acid on bleomycin-induced skin fibrosis through the repression of NADPH Oxidase 4 and TGF-\u03b21\/Smad 3 signaling pathways","volume":"41","author":"Ko\u00e7ak","year":"2022","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.ejphar.2025.177826_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2024.105986","article-title":"Porcupine inhibitors LGK-974 and ETC-159 inhibit Wnt\/\u03b2-catenin signaling and result in inhibition of the fibrosis","volume":"104","author":"Ko\u00e7ak","year":"2025","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.ejphar.2025.177826_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2025.106078","article-title":"Selective JAK-1 inhibitor Upadacitinib and peptide PD29 modulate the JAK and TGF-\u03b2\/Smad signaling pathways reducing experimental dermal fibrosis","author":"Ko\u00e7ak","year":"2025","journal-title":"Toxicol. Vitro"},{"issue":"11","key":"10.1016\/j.ejphar.2025.177826_bib24","first-page":"2125","article-title":"Mineralocorticoid receptor antagonists: 60 years of research and development","volume":"39","author":"Kolkhof","year":"2021","journal-title":"J. Hypertens."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177826_bib25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s00125-007-0886-7","article-title":"Oxidative stress: the vulnerable beta-cell","volume":"51","author":"Lenzen","year":"2008","journal-title":"Diabetologia (Berl.)"},{"issue":"11","key":"10.1016\/j.ejphar.2025.177826_bib26","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/aps.2012.33","article-title":"Pharmacokinetic\/pharmacodynamic studies on exenatide in diabetic rats","volume":"33","author":"Li","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177826_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-022-01658-7","article-title":"Triglyceride-glucose index and the risk of heart failure: evidence from two large cohorts and a Mendelian randomization analysis","volume":"21","author":"Li","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177826_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41574-022-00776-2","article-title":"Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice","volume":"19","author":"Lim","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177826_bib29","first-page":"1250","article-title":"Glucagon-like peptide-1 receptor activation attenuates angiotensin II-induced cardiomyocyte apoptosis through PKA and PI3K\/Akt-dependent pathways","volume":"61","author":"Liu","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.177826_bib30","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","article-title":"Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease","volume":"24","author":"Liu","year":"2015","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"2","key":"10.1016\/j.ejphar.2025.177826_bib31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4093\/dmj.2020.0282","article-title":"Epidemiology, pathophysiology, diagnosis and treatment of heart failure in diabetes","volume":"45","author":"Park","year":"2021","journal-title":"Diabetes Metab. J."},{"issue":"S2","key":"10.1016\/j.ejphar.2025.177826_bib32","article-title":"GLP-1 receptor agonists in type 1 diabetes: a promising adjunctive therapy?","volume":"18","author":"Pettus","year":"2016","journal-title":"Diabetes Technol. Therapeut."},{"issue":"11","key":"10.1016\/j.ejphar.2025.177826_bib33","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic mechanisms of diabetic heart disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2025.177826_bib34","first-page":"140","article-title":"Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function","volume":"130","author":"Rowlands","year":"2018","journal-title":"Free Radic. Biol. Med."},{"issue":"11","key":"10.1016\/j.ejphar.2025.177826_bib35","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","article-title":"Cardiac effects of incretin-based therapies: integrating mechanisms with clinical outcomes","volume":"114","author":"Ussher","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2025.177826_bib36","first-page":"14","article-title":"Myocardial oxygen consumption is increased in type 1 diabetic rats and correlates with left ventricular dysfunction","volume":"9","author":"van den Brom","year":"2010","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177826_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000520909","article-title":"Heart failure in patients with diabetes and chronic kidney disease: challenges and opportunities","volume":"12","author":"Vijay","year":"2022","journal-title":"Cardiorenal Med."},{"key":"10.1016\/j.ejphar.2025.177826_bib38","article-title":"Exenatide improved cardiac function in diabetic rats by regulating inflammation and oxidative stress","volume":"2014","author":"Wang","year":"2014","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.ejphar.2025.177826_bib39","first-page":"1","article-title":"Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention","author":"Wong","year":"2023","journal-title":"Nat. Rev. Cardiol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925005801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925005801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:21:17Z","timestamp":1778876477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925005801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"alternative-id":["S0014299925005801"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177826","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic effects of finerenone and exenatide on diabetes-induced heart failure: A combined approach targeting inflammation and oxidative stress","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"177826"}}